JPWO2022043538A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022043538A5 JPWO2022043538A5 JP2023513582A JP2023513582A JPWO2022043538A5 JP WO2022043538 A5 JPWO2022043538 A5 JP WO2022043538A5 JP 2023513582 A JP2023513582 A JP 2023513582A JP 2023513582 A JP2023513582 A JP 2023513582A JP WO2022043538 A5 JPWO2022043538 A5 JP WO2022043538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- amino acid
- acid sequence
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072113P | 2020-08-29 | 2020-08-29 | |
| US63/072,113 | 2020-08-29 | ||
| PCT/EP2021/073816 WO2022043538A1 (en) | 2020-08-29 | 2021-08-27 | Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539493A JP2023539493A (ja) | 2023-09-14 |
| JPWO2022043538A5 true JPWO2022043538A5 (enExample) | 2024-09-03 |
Family
ID=77821706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513582A Pending JP2023539493A (ja) | 2020-08-29 | 2021-08-27 | Ｂｃｌ－２阻害剤への低下した感度を有する患者の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240182590A1 (enExample) |
| EP (1) | EP4204098A1 (enExample) |
| JP (1) | JP2023539493A (enExample) |
| KR (1) | KR20230061421A (enExample) |
| CN (1) | CN116249519A (enExample) |
| AU (1) | AU2021334165A1 (enExample) |
| CA (1) | CA3188634A1 (enExample) |
| IL (1) | IL300996A (enExample) |
| MX (1) | MX2023002318A (enExample) |
| WO (1) | WO2022043538A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| KR20250134703A (ko) | 2018-05-11 | 2025-09-11 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법 |
| AU2023390486A1 (en) * | 2022-12-08 | 2025-07-03 | The Regents Of The University Of Colorado, A Body Corporate | Methods for identifying resistance or response to venetoclax/hypomethylating agent/anti-cd70 agent treatment for acute myeloid leukemia |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
| US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| JP2010513306A (ja) | 2006-12-14 | 2010-04-30 | メダレックス インコーポレーティッド | Ｃｄ７０に結合するヒト抗体およびその使用 |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN107266435A (zh) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
| US10391168B1 (en) * | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| EP3426655A1 (en) | 2016-03-10 | 2019-01-16 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| EP3468973A4 (en) | 2016-06-09 | 2020-02-26 | Dr. Reddy's Laboratories Ltd. | SOLID FORMS OF VENETOCLAX AND METHOD FOR PRODUCING VENETOCLAX |
| EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
| CN107648185A (zh) | 2016-07-25 | 2018-02-02 | 常州爱诺新睿医药技术有限公司 | 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法 |
| WO2018029711A2 (en) | 2016-08-12 | 2018-02-15 | Mylan Laboratories Limited | Process for the preparation of venetoclax |
| US10800777B2 (en) | 2016-10-14 | 2020-10-13 | Mylan Laboratories Limited | Polymorphic forms of VENCLEXTA |
| EP3333167A1 (en) | 2016-12-09 | 2018-06-13 | LEK Pharmaceuticals d.d. | Solid forms of venetoclax |
| WO2018157803A1 (zh) | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | 维奈妥拉的晶型及其制备方法 |
| WO2018167652A1 (en) | 2017-03-13 | 2018-09-20 | Laurus Labs Limited | Process for preparation of amorphous form of venetoclax |
| CN107089981A (zh) | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
-
2021
- 2021-08-27 EP EP21772989.6A patent/EP4204098A1/en active Pending
- 2021-08-27 CA CA3188634A patent/CA3188634A1/en active Pending
- 2021-08-27 AU AU2021334165A patent/AU2021334165A1/en active Pending
- 2021-08-27 IL IL300996A patent/IL300996A/en unknown
- 2021-08-27 KR KR1020237010275A patent/KR20230061421A/ko active Pending
- 2021-08-27 JP JP2023513582A patent/JP2023539493A/ja active Pending
- 2021-08-27 MX MX2023002318A patent/MX2023002318A/es unknown
- 2021-08-27 CN CN202180053199.2A patent/CN116249519A/zh active Pending
- 2021-08-27 WO PCT/EP2021/073816 patent/WO2022043538A1/en not_active Ceased
-
2023
- 2023-02-27 US US18/175,225 patent/US20240182590A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma | |
| Duda et al. | CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? | |
| AU2015296555B2 (en) | Flagellin compositons and uses | |
| JP7498564B2 (ja) | 急性骨髄性白血病治療のための抗－ｃｄ７０抗体ａｒｇｘ－１１０の使用 | |
| US11220548B2 (en) | Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody | |
| Cooper et al. | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades | |
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| WO2019189780A1 (ja) | 癌の治療及び／又は予防用医薬組成物 | |
| CN1373671A (zh) | 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者 | |
| CN110613845A (zh) | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 | |
| WO2025076288A1 (en) | Combination therapy for cancer treatment | |
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| El-Mallawany et al. | Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma | |
| JP2018516244A5 (enExample) | ||
| JP2022519649A (ja) | がんの診断および治療方法 | |
| JP2023539493A (ja) | Ｂｃｌ－２阻害剤への低下した感度を有する患者の治療方法 | |
| JPWO2020127503A5 (enExample) | ||
| JP2020500161A5 (enExample) | ||
| US20220024991A1 (en) | Engineered flagellin-derived compositions and uses | |
| JPWO2022043538A5 (enExample) | ||
| US20210214448A1 (en) | Ccr5 binding agent for the treatment of ccr5 positive metastatic cancer | |
| KR20250131777A (ko) | 암의 치료 및 예방을 위한 조합물 | |
| WO2024249339A1 (en) | Combined rtk and sumo inhibition for cancer therapy | |
| JPWO2023099622A5 (enExample) | ||
| CN115611981A (zh) | 抗pd-1抗体在治疗外周t细胞淋巴瘤中的应用 |